Meta-analysis Of Cannabis Based Treatments For Neuropathic And Multiple Sclerosis-related Pain
| Effect | Decrease |
| Values | 0-10 point scale. Mean difference from baseline and SE. 1.7 (0.7). Placebo: 0.8 (0.4) |
| Trial Design | Meta analysis |
| Trial Length | n/a |
| Number of Subjects | 0 |
| Sex | Both Genders |
This was a meta-analysis of randomized, double-blind, placebo-controlled trials that used cannabis-based drugs to treat multiple sclerosis or comparable neuropathic pain in adults. Six trials involved CBD with THC, five involved cannabidiol, and three involved dronabinol (only the combination counts for this page).Funding issues for this study:
There was a moderate, statistically significant improvement in pain from THC + CBD buccal spray compared with baseline in the six trials. The difference was greater than placebo, though placebo was based on a larger number of studies and the two weren't compared statistically.
"This study was funded by Bayer Inc., Toronto,
Canada."
